Home › Research › Treatments
Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial
Saito S, Suzuki K, Ohtani R, Maki T, Kowa H, Tachibana H, Washida K, Kawabata N et al.. JAMA network open, 2023-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Results The full analysis set included 159 patients (66 [41.5%] male; mean [SD] age, 75.6 [5.2] years) who received placebo or cilostazol at least once. There was no statistically significant difference between the placebo and cilostazol groups for the primary outcome.
What this study adds
Evidence grade: High
This is a trial of 159 participants. In this randomized clinical trial of 159 patients with mild cognitive impairment, there was no statistically significant difference between cilostazol and placebo for the primary outcome. Reported effect size: 41.5%; 2.5%; 3.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Saito, S., Suzuki, K., Ohtani, R., Maki, T., Kowa, H., Tachibana, H., et al. (2023). Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2023.44938
Vancouver
Saito S, Suzuki K, Ohtani R, Maki T, Kowa H, Tachibana H, et al. Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA network open. 2023. doi:10.1001/jamanetworkopen.2023.44938. PMID: 38048134.
BibTeX
@article{saito2023-38048134,
author = {Saito, S. and Suzuki, K. and Ohtani, R. and Maki, T. and Kowa, H. and Tachibana, H. and Washida, K. and Kawabata, N. and others},
title = {{Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial}},
journal = {JAMA network open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.44938},
pmid = {38048134},
url = {https://doi.org/10.1001/jamanetworkopen.2023.44938}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The full analysis set included 159 patients (66 [41.5%] male; mean [SD] age, 75.6 [5.2] years) who received placebo or cilostazol at least once.
- There was no statistically significant difference between the placebo and cilostazol groups for the primary outcome.
Why it matters
In this randomized clinical trial of 159 patients with mild cognitive impairment, there was no statistically significant difference between cilostazol and placebo for the primary outcome. The study did not find cilostazol effective for this purpose.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants159
- Effect size41.5%; 2.5%; 3.8%
- Evidence strengthHigh
How this study scored 69/100
Published in a leading specialty journal, and it is a randomized controlled trial. We have no data on senior author's track record, so that was left out: it earned 66 of the 96 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA network open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 159 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 16 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 2 / 6 | Cited 2.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Kyoto University: institution h-index 1,156 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 15 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38048134) |
| Free to read | 2 / 2 | Free to read |
| Points | 66 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 66 of the 96 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2023.44938
- PubMed: 38048134
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.